Danish Center for Sleep Medicine Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2016
NCT02761161
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Danish Center for Sleep Medicine

Active Ingredients

Drugs in Phase 4 Trials (1)

mianserin (1 trial)

Drugs in Phase 2 Trials (2)

cannabidiol (Epidiolex) (1 trial)

risperidone (risperdal) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyssomnias (Phase 4)

Parasomnias (Phase 4)

Psychotic Disorders (Phase 2)

Sleep Wake Disorders (Phase 4)

Stress Disorders, Post-Traumatic (Phase 4)

Stress Disorders, Traumatic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3